NL-OMON55086
Completed
N/A
Prospective seizure prediction in epileptic patients using VOC analysis by electronic nose (pilot) - EPIC study
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- convulsions
- Sponsor
- Stichting Epilepsie Instellingen Nederland
- Enrollment
- 4
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
Trial is onging in other countries
Investigators
Eligibility Criteria
Inclusion Criteria
- •\>\= 18 years of age
- •Admitted to SEIN for video\-EEG recording
- •Diagnosed with epilepsy
- •High seizure frequency (1 or more per week), or admitted for multiple days of
- •video\-EEG as part of epilepsy surgery track with tapering of anti\-seizure
- •Mentally competent and with no learning disabilities
Exclusion Criteria
- •Recent (\< 12 hours) intake of alcohol
- •Psychogenic Nonepileptic Seizures (PNES), without comorbidity of epilepsy or
- •with high level of doubt of epilepsy diagnosis
- •Unwillingness or inability to comply with the study protocol for any other
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
N/A
Treatment of electroencephalographic status epilepticus after cardiopulmonary resuscitatioNL-OMON50403Ziekenhuis Rijnsate171
Completed
N/A
A multicentre Prospective study in pAtients undergoing ventral herNia repair by open approach with intrA-peritoneal positioning using parietex* Composite vEntral pAtch.hernia / abdominal wall defect10041297NL-OMON40149Covidien8
Not Yet Recruiting
N/A
Seizures Detection in Real Life SettingEpilepsy; SeizureFocal EpilepsyNCT05635396Reliev Technologies12
Completed
Phase 2
Prospective evaluation of the predictive value of a circulating tumor cell (CTC) sensitivity profile to Cisplatin chemotherapy in metastatic breast cancer patientsMetastatic breast cancermetastatic mammary cancer10006291NL-OMON44123Erasmus MC, Universitair Medisch Centrum Rotterdam67
Completed
Phase 3
A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 2/3 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)ALSAmyotrophic Lateral Sclerosis10011305NL-OMON44970AB Science10